|Articles|April 1, 2004

The Brave (but maybe not so New) World of adolescent medicine

Not until 1980 did experiences in the care of teenagers become a requirement of pediatric residency training, and not until 1997 was a month-long rotation in adolescent medicine made a mandatory part of residency training.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

Edward Hook, MD, reacts to the FDA approval of zoliflodacin for uncomplicated urogenital gonorrhea

ByEdward Hook, MD

December 12th 2025

FDA approves Nuzolvence (zoliflodacin) for treatment of uncomplicated urogenital gonorrhea in 12 years and up

ByMorgan Ebert, Managing Editor

December 12th 2025

The benefits of gepotidacin for urogenital gonorrhea with Angela Hasler, APRN, CPNP-PC

By Angela Hasler, APRN, CPNP-PC

December 12th 2025

FDA approves powder formulation of trofinetide for Rett syndrome

ByMorgan Ebert, Managing Editor,Joshua Fitch, Senior Editor

December 12th 2025

FDA approves berotralstat for patients aged 2 to 11 years with hereditary angioedema | Image credit: Contemporary Pediatrics

FDA approves berotralstat for patients aged 2 to <12 years with hereditary angioedema

ByJoshua Fitch, Senior Editor

December 12th 2025

Latest CME

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

In-Person + Virtual Event

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

January 23, 2026

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

The Brave (but maybe not so New) World of adolescent medicine

Newsletter

Related Content

Edward Hook, MD, reacts to the FDA approval of zoliflodacin for uncomplicated urogenital gonorrhea

FDA approves Nuzolvence (zoliflodacin) for treatment of uncomplicated urogenital gonorrhea in 12 years and up

The benefits of gepotidacin for urogenital gonorrhea with Angela Hasler, APRN, CPNP-PC

FDA approves powder formulation of trofinetide for Rett syndrome

FDA approves berotralstat for patients aged 2 to <12 years with hereditary angioedema

Latest CME

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

FDA approves gepotidacin as oral treatment for urogenital gonorrhea

Reports: FDA launching safety review of nirsevimab and clesrovimab for RSV

FDA approves powder formulation of trofinetide for Rett syndrome

FDA approves Waskyra as first gene therapy for Wiskott-Aldrich syndrome

FDA approves berotralstat for patients aged 2 to <12 years with hereditary angioedema